ARVN - Arvinas Inc Stock Price, Fair Value and News

29.64USD+0.12 (+0.41%)Market Closed

Market Summary

USD29.64+0.12

Market Closed

0.41%

ARVN Stock Price

View Fullscreen

ARVN RSI Chart

ARVN Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-5.72

Price/Sales (Trailing)

27.2

EV/EBITDA

-5.9

Price/Free Cashflow

-5.7

ARVN Price/Sales (Trailing)

ARVN Profitability

EBT Margin

-448.41%

Return on Equity

-58.19%

Return on Assets

-29.26%

Free Cashflow Yield

-17.55%

ARVN Fundamentals

ARVN Revenue

Revenue (TTM)

78.5M

Rev. Growth (Yr)

-22.15%

Rev. Growth (Qtr)

-15.53%

ARVN Earnings

Earnings (TTM)

-354.8M

Earnings Growth (Yr)

15.26%

Earnings Growth (Qtr)

55.17%

Breaking Down ARVN Revenue

Last 7 days

3.9%

Last 30 days

14.6%

Last 90 days

-8.4%

Trailing 12 Months

35.2%

How does ARVN drawdown profile look like?

ARVN Financial Health

Current Ratio

4.94

Debt/Equity

Debt/Cashflow

-505.86

ARVN Investor Care

Shares Dilution (1Y)

28.15%

Diluted EPS (TTM)

-6.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	137.3M	158.1M	159.4M	78.5M
2022	74.5M	102.8M	126.8M	131.3M
2021	25.2M	24.9M	26.6M	53.5M
2020	45.2M	46.9M	24.5M	25.9M
2019	14.2M	14.8M	41.5M	43.0M
2018	10.0M	11.7M	13.5M	14.3M
2017	0	0	0	7.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

CEO	Dr. John G. Houston Ph.D.
WEBSITE	arvinas.com
INDUSTRY	Biotechnology
EMPLOYEES	415

Arvinas Inc Frequently Asked Questions

What is the ticker symbol for Arvinas Inc? What does ARVN stand for in stocks?

ARVN is the stock ticker symbol of Arvinas Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arvinas Inc (ARVN)?

As of Fri Jul 26 2024, market cap of Arvinas Inc is 2.03 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARVN stock?

You can check ARVN's fair value in chart for subscribers.

Is Arvinas Inc a good stock to buy?

The fair value guage provides a quick view whether ARVN is over valued or under valued. Whether Arvinas Inc is cheap or expensive depends on the assumptions which impact Arvinas Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARVN.

What is Arvinas Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, ARVN's PE ratio (Price to Earnings) is -5.72 and Price to Sales (PS) ratio is 27.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARVN PE ratio will change depending on the future growth rate expectations of investors.